A1210477
|
AML
|
THP-1 U937
|
venetoclax
|
[337]
|
A1210477
|
Breast
|
MDA-MB-231 cells
|
TRAIL
|
[338]
|
A1210477
|
Cervical
|
SiHa and CaSki
|
navitoclax
|
[139]
|
A1210477
|
CML
|
K562, K562/R
|
EE-84
|
[339]
|
A1210477
|
CRC
|
RKO, HT29, A375
|
cobimetinib
|
[340]
|
A1210477
|
DLBCL
|
U-2946
|
navitoclax
|
[341]
|
A1210477
|
PC, GC, NSCLC, MM
|
BxPC-3, EJ-1, H23, and OPM-2
|
navitoclax
|
[70]
|
A1210477
|
HNSCC
|
PCI15B, Detroit 562, MDA686LN, and HN30
|
navitoclax
|
[342]
|
A1210477
|
nHL
|
SU-DHL-4, WSU-NHL, WSU-DLCL2, KARPAS-422
|
venetoclax
|
[343]
|
AMG-176
|
CLL
|
Patient samples (5)
|
venetoclax
|
[344]
|
AZD-5991
|
AML
|
OCI-AML3 and MCL-1-OE Molm13 and MV4–11
|
venetoclax
|
[345]
|
AZD5991
|
MM
|
NCI-H929
|
bortezomib, venetoclax
|
[73]
|
GDC-0941
|
Breast
|
MDA-MB-231, SKBR3
|
ABT-737
|
[346]
|
Mim1
|
Glioblastoma
|
U87mg
|
temozolomide
|
[347]
|
Mim1
|
Melanoma
|
C32 melanoma cells
|
dacarbazine
|
[348]
|
Mim1
|
MM
|
Colo829
|
dacarbazine
|
[349]
|
S63845
|
AML
|
OCI-AML3, MOLM-13, OCI-AML2
|
trametinib/HDM201
|
[350]
|
S63845
|
AML
|
Primary samples
|
venetoclax
|
[351]
|
S63845
|
AML
|
MOML-13, SKM-1,
|
trametinib
|
[352]
|
S63845
|
AML
|
Cell lines and primary cells
|
venetoclax
|
[353]
|
S63845
|
Breast
|
SK-BR-3
|
docetaxel, trastuzumab, lapatinib
|
[354]
|
S63845
|
CRC
|
HCT116
|
regorafenib
|
[355]
|
S63845
|
Mantle cell lymphoma
|
Patient-derived xenografts
|
venetoclax
|
[356]
|
S63845
|
Melanoma
|
Patient samples
|
navitoclax
|
[357]
|
S63845
|
Melanoma
|
MeWo
|
TRAIL resistance
|
[358]
|
S63845
|
Myeloma
|
U266 xenograft
|
venetoclax
|
[359]
|
S63845
|
MM
|
MOL-P8, OPM-2, NCI-H929
|
venetoclax, bortezomib
|
[360]
|
S63845
|
MM
|
RPMI-8226 xenograft
|
venetoclax
|
[361]
|
S63845
|
Nasopharyngeal carcinoma
|
CNE-2, 5-8F
|
venetoclax
|
[293]
|
S63845
|
T-ALL
|
Zebrafish T-ALL cells
|
venetoclax
|
[304]
|
VU661013
|
AML
|
MV-4-11, AML-001/2, patient xenografts
|
venetoclax
|
[76]
|
VU661013
|
Breast
|
HCC1428, MCF7, T47D
|
navitoclax
|
[362]
|